A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

European Journal of Cancer

Volumn 63, Issue , 2016, Pages 55-63

  Fiedler, W ^a   Dedosso, S ^b   Cresta, S ^c   Weidmann, J ^a   Tessari, A ^c   Salzberg, M ^d   Dietrich, B ^d   Baumeister, H ^d   Goletz, S ^d   Gianni, L ^e   Sessa, C ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d GLYCOTOPE GMBH   (Germany)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Glyco optimised monoclonal antibody; Glycopeptide epitope; MUC1; Phase I; Solid tumours

Indexed keywords

COMPLEMENT COMPONENT C3A; DRUG ANTIBODY; EOSINOPHIL CATIONIC PROTEIN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MUCIN 1; PANKOMAB GEX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PANKOMAB-GEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; CANCER PATIENT; CHILL; COUGHING; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFUSION RELATED REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OVARY CANCER; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TACHYCARDIA; TREATMENT RESPONSE; VERY ELDERLY; CARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN-1;

EID: 84974621186     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.05.003     Document Type: Article

References (27)

1. S. Zotter, P.C. Hageman, A. Lossnitzer, W.J. Mooi, and J. Hilgers Tissue and tumor distribution of human polymorphic epithelial mucin Cancer Rev 11-12 1988 55 101
2. G.A. Dent, C.J. Civalier, M.E. Brecher, and S.A. Bentley MUC1 expression in hematopoietic tissues Am J Clin Pathol 111 1999 741 747
3. U. Karsten, and S. Goletz What makes cancer stem cell markers different? SpringerPlus 2 2013 301
4. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 2009 874 885
5. U. Karsten, S. von Mensdorff-Pouilly, and S. Goletz What makes MUC1 a tumor antigen? Tumor Biol 26 2005 217 220
6. C.L. Hattrup, and S.J. Gendler Structure and function of the cell surface (tethered) mucins Annu Rev Physiol 70 2008 431 457
7. J. Burchell, and J. Taylor-Papadimitriou Effect of modification of carbohydrate side chains on the reactivity of antibodies with core protein epitopes of the MUC1 gene product Epithelial Cell Biol 2 1993 155 162
8. U. Karsten, C. Diotel, G. Klich, H. Paulsen, S. Goletz, S. Müller, and et al. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation Cancer Res 58 12 1998 2541 2549
9. U. Karsten, N. Serttas, H. Paulsen, A. Danielczyk, and S. Goletz Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1) Glycobiology 14 8 2004 681 692
10. C.K. Tang, M. Katsara, and V. Apostolopoulos Strategies used for MUC1 immunotherapy: human clinical studies Expert Rev Vaccines 7 7 2008 963 975
11. S. von Mensdorff-Pouilly, E. Petrakou, P. Kenemans, and et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides Int J Cancer 86 5 2000 702 712
12. A. Danielczyk, R. Stahn, D. Faulstich, A. Löffler, A. Märten, U. Karsten, and et al. PankoMab: a potent new generation anti-tumour MUC1 antibody Cancer Immunol Immunother 55 11 2006 1337 1347
13. X.N. Fan, U. Karsten, S. Goletz, and Y. Cao Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas Pathol Res Pract 206 8 2010 585 589
14. A. Natsume, R. Niwa, and M. Satoh Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC Drug Des Devel Ther 3 2009 7 16
15. V. Goede, C. Klein, and S. Stilgenbauer Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin's lymphomas: a glycoengineered Type II CD20 antibody Oncol Res Treat 38 4 2015 185 192
16. S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, and et al. Rituximab dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res 64 2004 4664 4669
17. S. Herter, M.C. Birk, C. Klein, C. Gerdes, P. Umana, and M. Bacac Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity J Immunol 192 5 2014 2252 2260
18. G. Ragupathi, N.X. Liu, C. Musselli, S. Powell, K. Lloyd, and P.O. Livingston Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity J Immunol 174 9 2005 5706 5712
19. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
20. Erbitux - Annex I - Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000558/WC500029119.pdf.
21. R. Bruno, C.B. Washington, J.F. Lu, G. Lieberman, L. Banken, and P. Klein Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer Cancer Chemother Pharmacol 56 4 2005 361 369
22. T. Kumai, K. Oikawa, N. Aoki, S. Kimura, Y. Harabuchi, and H. Kobayashi Assessment of the change in cetuximab induced ADCC activity of NK cells by steroid Head Neck 2015 10.1002/hed.23906 [Epub ahead of print]
23. E. Maggi, A. Vultaggio, and A. Matucci Acute infusion reactions induced by monoclonal antibody therapy Expert Rev Clin Immunol 7 1 2011 55 63
24. D. Dian, W. Janni, C. Kuhn, and et al. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies Onkologie 32 5 2009 238 244
25. A. Kuemmel, K. Single, F. Bittinger, A. Faldum, L.H. Schmidt, M. Sebastian, and et al. TA-MUC1 epitope in non-small cell lung cancer Lung Cancer 63 1 2009 98 105
26. D. Dian, M. Lenhard, D. Mayr, S. Heublein, U. Karsten, S. Goletz, and et al. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8 Histol Histopathol 28 2 2013 239 244
27. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, C. Lebbé, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 23 2009 7412 7420